Protein C News and Research

RSS

Research sheds light on early embryogenesis, genetic disease

Chromosome 22q11 deletion syndrome (also known as DiGeorge syndrome) is the most common human chromosome deletion syndrome, having an estimated incidence of at least one in 4,000 live births.

15 May 2010

U.S. Patent and Trademark Office grants patent to Historx's AQUA technology

HistoRx , Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for determining a cancer patient's prognosis based on sub-cellular localization of biomarkers.

15 May 2010

HSPH researchers succeed in locking malaria parasites within infected blood cells

Harvard School of Public Health researchers and colleagues seeking to block invasion of healthy red blood cells by malaria parasites have instead succeeded in locking the parasites within infected blood cells, potentially containing the disease.

15 May 2010

Chlorophyll-rich beverage offers immense health benefits

Summer action movies may call for suspension of disbelief from audiences, but one superhero's penchant for a chlorophyll-rich drink to detoxify his body has real benefits, according to one medical expert.

15 May 2010

TRPV4 activity vital to prevent skin dehydration

Japanese research group led by Prof. Makoto Tominaga and Dr. Takaaki Sokabe (National Institute for Physiological Sciences: NIPS) found that TRPV4 ion channel in skin keratinocytes is important for formation and maintenance of barrier function to prevent dehydration. Their finding was reported in the Journal of Biological Chemistry.

15 May 2010

Scientists look for new ways to fight TB

Scientists looking for new ways to fight tuberculosis have their sights set on a structure essential to the bacterium's survival. Disabling this structure could kill the microbes in the infected host and thwart TB infections. In a study appearing online May 11, 2010, in EMBO J, the journal of the European Molecular Biology Organization, scientists from the U.S. Department of Energy's Brookhaven National Laboratory, Stony Brook University, and Weill Cornell Medical College describe new features of how this structure, known as a proteasome, is put together and how it works.

14 May 2010

NanoViricides signs research and development agreement with Dr. Ken S. Rosenthal's laboratory

NanoViricides, Inc., reports that it has signed a research and development agreement with Dr. Ken S. Rosenthal's laboratory at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

14 May 2010

Researchers determine how cells regulate chromosome/microtubule interface

Whitehead Institute researchers have determined a key part of how cells regulate the chromosome/microtubule interface, which is central to proper chromosomal distribution during cell division.

14 May 2010

New research to improve treatment for oesophageal and upper stomach cancer

Poor diet, too much alcohol, smoking and increasing obesity could be leading to an epidemic of oesophageal and upper stomach cancer, according to a leading UK team of specialists at The University of Nottingham and Nottingham University Hospitals.

14 May 2010

Each melanoma cell capable of cancer stem cell behavior: Study

Scientists at The Wistar Institute offer a new explanation for the persistent ability of melanoma cells to self-renew, one of the reasons why melanoma remains the deadliest form of skin cancer. The concept of the "dynamic stemness" of melanoma can explain why melanoma cells behave like both conventional tumor cells and cancer stem cells.

14 May 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex, Inc. today announced its financial results for the first quarter ended March 31, 2010. The Company also announced that it has initiated a Phase I single ascending dose trial of INX-189, its lead HCV nucleotide polymerase inhibitor, in healthy volunteers under an Investigational New Drug application with the U.S. Food and Drug Administration.

14 May 2010

Mild-mannered organelles can detect virus invasion signals: Researchers

Within cells, an ancient antiviral duo can deliver a one-two knockout to thwart invading viruses, report researchers who have just unmasked the cellular sidekick that throws the first punch. The findings mean scientists must rethink the design of antiviral immunity and how the body fends off viruses of all types, including influenza and HIV.

14 May 2010

Immunosuppressive drug sirolimus improves kidney health of patients with ADPKD: Study

The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

14 May 2010

caprotec bioanalytics closes EUR 4 million Series B Financing Round

caprotec bioanalytics GmbH today announced the closing of a EUR 4 million ($5.1M) Series B Financing Round with existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors. The proceeds will enable further development and marketing of the Company's proprietary CCMS (Capture Compound Mass Spectrometry) platform technology for analyzing complex protein mixtures.

14 May 2010

UGA researchers discover SERS method to identify rotavirus strains, genotypes

Using nanotechnology and a patented signal enhancing technique developed at the University of Georgia, UGA researchers have discovered a rapid, sensitive and cost-effective method to detect and identify a number of rotavirus strains and genotypes in less than one minute with greater than 96 percent accuracy.

14 May 2010

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.

13 May 2010

Researchers provide better understanding of anti-cell death proteins and potential antagonist to defeat them

Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

Researchers develop new approach to immunotherapy of cancer

Harnessing the immune system is emerging as one of the most promising new ways to fight cancer. Most cancer cells are eliminated by the immune system; however, over a lifetime, a few may escape this immune surveillance and lead to tumors and metastases. Hence a formidable opportunity has been to find ways to make the immune system recognize the tumor as a foreign body and trigger a response.

13 May 2010

Research sheds light on prenatal heart formation, chromosome 22q.11 deletion syndrome

Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.

13 May 2010